Berberine is one of 179 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
146 competitors in Cardiovascular Disease
Isordil
Dobutrex
Thalitone
Enbrel
Timolol Maleate
Verquvo
Bumex
Colcrys
Pelacarsen
Cagrilintide
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources
Details